摘要
目的:探讨原发性头颈部鳞癌ＣＤ４４Ｖ６、Ｐ５３及ＰＣＮＡ蛋白的表达及临床意义。方法:采用ＳＰ免疫组化染色方法,检测８０例头颈部鳞癌ＣＤ４４Ｖ６、ｐ５３及ＰＣＮＡ蛋白的表达。结果:①头颈部鳞癌ＣＤ４４Ｖ６表达阳性率为３１．３%,淋巴结转移组阳性率显著低于无淋巴结转移组(Ｐ ＜０．０５),低分化癌组阳性表达率低于高分化癌组(Ｐ＜０．０５);②Ｐ５３蛋白在淋巴结转移组阳性率显著高于无淋巴结转移组(Ｐ＜０．０１),低分化癌组阳性率高于高分化癌组(Ｐ＜０．０１);③ＰＣＮＡ强阳性表达在淋巴结转移、低分化癌与无淋巴结转移、高分化癌均有显著差异(Ｐ＜０．０１)。结论:头颈部鳞癌 ＣＤ４４Ｖ６低度表达、Ｐ５３及ＰＣＮＡ蛋白的高表达,提示肿瘤恶性度高、易发生淋巴结转移。
ve: To evaluate the clinical significance of expression of CD44V6 ,P53 protein and proliferating cell nuclear antigen (PCNA) in head and neck squamous cell carcinoma. There were 48 males and 32 females, ranging in age from 38 to 77 years old. The primary carcinoma was 38 in sinus, 27 in oral and 15 in tonsil. Cervical node metastasis was 34 cases. Methods: The expressions of CD44 V6, P53 protein and PCNA were determined by method of immunohistochemical SP in 80 patients of head and neck squamous cell carcinoma. Results: The positive expression rates of CD44V6 and P53 protein were 31. 3% (25/80) and 60. 0% (45/80) respectively. The higher and lower expression of PCNA were 43. 75% (35/80) and 56. 25% (45/80) respectively. The positive rate of CD44V6 was 17. 6% (6/34) in group of patients with node lymph metastasis which showed significantly lower than that in group of patients with negative metastasis (41. 3%, 19/46) (P<0. 05). The positive rate of CD44V6 in poor grading cancer (18. 9% ,7/37) was significantly lower than that in high differentiation cancer (41. 8%, 18/43) (.P<0. 05). The positive rate of P53 ws significantly lower in cancer without lymph node involvement (47. 8%,22/46) than that with lymph node involvement (76. 3%,26/34)(P <0. 01). The positive rate of P53 in poor grading cancer (75. 7% ,28/37) was significantly higher than that in high differentiation cancer (40. 5% , 20/43) (P < 0. 01). Conclusion: The present study suggested that the lymph node metastasis should be correlated with low level expression of CD44V6, high level expression of P53 protein and the higher expressions of PCNA in head and neck squamous cell carcinoma.
出处
《耳鼻咽喉（头颈外科）》
2002年第2期98-100,W002,共4页
Chinese Arch Otolaryngology-Head Neck Surg
